The first of a series of educational webinars on the latest developments in gene therapy for Gaucher treatment, focusing on AVROBIO's lentiviral gene therapy, an ex vivo gene therapy approach for Type 1 Gaucher disease, will take place on Monday 21st September from 3-4:30pm (GMT).
The main speaker will be AVROBIO's Chief Scientific Officer, Chris Mason and Prof Timothy Cox from Cambridge University will moderate.
Click here for more information about AVROBIO's gene therapy.
Timothy Cox is Professor of Medicine Emeritus and Director of Research at the University of Cambridge. A lab scientist and practising physician at Addenbrooke’s hospital, he studies orphan diseases and founded the first national specialised treatment centre for Gaucher disease in the UK.
Chris Mason is a Founder and Chief Science Officer at AVROBIO, a clinical-stage, gene therapy company based in Cambridge, Massachusetts [NASDAQ: AVRO]. He is a clinician-scientist with 30 years of cell and gene therapy experience including Full Professor of Cell and Gene Therapy in the Advanced Centre for Biochemical Engineering, University College London. He is an inventor, Founder and Non-Executive Director of OriBiotech, focused on next-generation fully-automated cell processing. Chris is on a number of companies’ SABs, and is on the SAB of the UK Cell and Gene Therapy Catapult. Chris is Senior Editor of the journals; ‘Cell and Gene Therapy Insights’ and ‘Regenerative Medicine’.